8-K - SCYNEXIS, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

SCYNEXIS filed a Form 8-K on March 31, 2026 disclosing its ADPKD asset acquisition, $40M PIPE financing, and corporate update via a furnished presentation.

Key Takeaways

1Acquired global rights to SCY-770 ADPKD asset from Poxel with no royalty obligations

2Raised $40M in PIPE financing, extending cash runway to mid-2029

3SCY-770 Phase 2 ADPKD trial initiation expected in Q4 2026

4GSK BREXAFEMME partnership eligible for up to $146M in sales milestones plus royalties

5SCY-770 has potential accelerated approval path via FDA-endorsed TKV surrogate endpoint

Current Report Details

Event Type

Regulation Fd

Exhibits Only

Disclosure

Voluntary

Variant

8-K

Items Reported

7.01

of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is being “furnished” and will not, except to the extent required by applicable law or regula

Regulation Fd

9.01

| Financial Statements and Exhibits. | |---|---| (d) Exhibits. Exhibit No.: 99.1 | Description: Corporate presentation dated March 2026 Exhibit No.: 104 | Descr

Exhibits Only

Source Document

Transaction Details

Acquisition / Disposition

Target: Global rights to SCY-770 (AMPK activator for ADPKD) from Poxel
Consideration: $8M upfront, $8M development milestones, up to $180M commercial milestones, no royalties
Structure: Asset acquisition of global development and commercial rights

•Phase 2 trial initiation expected Q4 2026
•Early Phase 2 efficacy readout expected 2H 2027

Exhibits (2)

8-K

99.1

EX-99.1